Skip to content
New: 30 more Indian companies explained, from Ather and Pine Labs to IDBI Bank

Compare · Healthcare

Dr. Reddy's vs Zydus Lifesciences: how their businesses differ

The same facts for both companies, in the same order, from each company's own page and filings. It is not a ranking.

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

How they differ

In FY26, Dr. Reddy's revenue of ₹33,700 cr was about 1.2 times Zydus Lifesciences' ₹27,148 cr (Cityfort calculation: one divided by the other).

Dr. Reddy's largest segment is Global Generics, 88.9% of revenue in FY26; Zydus Lifesciences' largest segment is Pharmaceuticals, 82.6% of revenue in FY26.

India brought in 19.2% of Dr. Reddy's revenue in FY26; India brought in 35.8% of Zydus Lifesciences' revenue in FY26.

Dr. Reddy's largest payer group is Buyers of finished medicines, 88.9% of revenue (FY26); Zydus Lifesciences' largest payer group is Buyers in the US, 43.2% of revenue (FY26).

Zydus Lifesciences' page lists Dr. Reddy's among its competitors; Dr. Reddy's page does not list Zydus Lifesciences.

Sources: Dr. Reddy's S11, S1, S12, S2 · Zydus Lifesciences S6, S1

Each company in 5 points

Dr. Reddy's

  1. 1 · What it sells

    The company makes generic and branded medicines and the active ingredients that go into them, and its FY26 revenue from operations was ₹33,700 crore.

    Sources and detail on the Dr. Reddy's page
  2. 2 · Who pays it

    In FY26, customers in the US paid 35.1% of the company's revenue, customers in India 19.2%, Russia 10.4% and all other countries 35.3%.

    Sources and detail on the Dr. Reddy's page
  3. 3 · What it keeps from ₹100

    Of every ₹100 that came in during FY26, including ₹1,358 crore of other income, the company kept ₹12.0 as profit for shareholders, and its operating EBITDA margin on revenue was 19.1% (Cityfort calculation, after ₹352 crore of write-downs).

    Sources and detail on the Dr. Reddy's page
  4. 4 · Where the operating profit comes from

    Global Generics earned ₹16,970 crore of the company's ₹17,728 crore FY26 gross profit, while active ingredients and services (PSAI) earned ₹600 crore.

    Sources and detail on the Dr. Reddy's page
  5. 5 · The one thing to watch

    US lenalidomide exclusivity ended in Jan 2026, and the company's North America revenue was ₹2,489 crore in Q2 FY27, 23% lower than a year earlier by its own count.

    Sources and detail on the Dr. Reddy's page

Zydus Lifesciences

  1. 1 · What it sells

    Zydus Lifesciences makes generic medicines for the US, branded medicines for India, consumer health products and orthopaedic implants, and its FY26 revenue from operations was ₹27,148 crore.

    Sources and detail on the Zydus Lifesciences page
  2. 2 · Who pays it

    In FY26, buyers in the US paid 43.2% of Zydus's revenue, buyers in India 35.8%, Europe 9.9% and other countries 11.2%.

    Sources and detail on the Zydus Lifesciences page
  3. 3 · What it keeps from ₹100

    Of every ₹100 that came in during FY26, Zydus kept ₹18.4 as profit after ₹1.9 of one-off charges and with ₹4.6 of currency gains counted against costs, and its profit before one-off items, joint-venture share and tax was ₹7,203 crore.

    Sources and detail on the Zydus Lifesciences page
  4. 4 · Where the operating profit comes from

    Pharmaceuticals earned ₹7,049 crore of segment profit before one-off items and tax in FY26, consumer products ₹267 crore, and medical technologies lost ₹113 crore.

    Sources and detail on the Zydus Lifesciences page
  5. 5 · The one thing to watch

    Net debt (Cityfort calculation) went from net cash of ₹4,643 crore on 31 Mar 2025 to ₹8,034 crore on 30 Sep 2026, and the company put its net debt at 0.62 times EBITDA on its own measure.

    Sources and detail on the Zydus Lifesciences page

Where each ₹100 went

Each company's own receipt for its latest full financial year, with matching lines in the same order where both have them.

Dr. Reddy's

Where ₹100 went · FY26

Where ₹100 of Dr. Reddy's's money went in FY26
Materials and goods bought₹34.9
Employees₹17.1
Depreciation and amortisation₹5.9
Other running costs (incl. write-downs)₹25.7
Interest₹1.1
Income tax₹3.5
Kept as profit for shareholders₹12.0
Total₹100

Cityfort calculation from the FY26 audited results: each line ÷ ₹35,110 crore that came in (revenue ₹33,700 crore, other income ₹1,358 crore, and ₹52 crore from associates and minority partners' share of losses). Other running costs include ₹352 crore of write-downs. ₹12.0 was kept as profit; rounded lines add to 100.2.

Zydus Lifesciences

Where ₹100 went · FY26

Where ₹100 of Zydus Lifesciences's money went in FY26
Materials and goods bought₹26.4
Employees₹16.0
Depreciation and amortisation₹4.9
Other running costs (after currency gains)₹25.2
One-off charges₹1.9
Interest, tax and minority owners' share, less joint-venture profit₹7.3
Kept as profit for shareholders₹18.4
Total₹100

Of every ₹100 that came in (revenue ₹27,148 crore + other income ₹510 crore), from the money flow above; each line ÷ ₹27,658 crore × 100 (Cityfort calculation).

Line items differ because each company groups its costs its own way in its filings. Only on Dr. Reddy's receipt: Other running costs (incl. write-downs); Interest; Income tax. Only on Zydus Lifesciences' receipt: Other running costs (after currency gains); One-off charges; Interest, tax and minority owners' share, less joint-venture profit.

Sources: Dr. Reddy's S11, S1, S12 · Zydus Lifesciences S6, S1

Revenue, net profit and free cash flow

Up to five financial years for each company, drawn on one shared scale per measure. Amounts in ₹ crore as each company reports them.

Revenue

Dr. Reddy's

Zydus Lifesciences

Both charts use the same scale. Indian financial years (April to March).
See the numbers
Revenue of Dr. Reddy's and Zydus Lifesciences by financial year, ₹ crore
Dr. Reddy's yearDr. Reddy's revenueZydus Lifesciences yearZydus Lifesciences revenue
FY22₹21,545 crFY22₹15,110 cr
FY23₹24,670 crFY23₹17,237 cr
FY24₹28,011 crFY24₹19,547 cr
FY25₹32,644 crFY25₹23,242 cr
FY26₹33,700 crFY26₹27,148 cr

Net profit

Dr. Reddy's

Zydus Lifesciences

Both charts use the same scale. Indian financial years (April to March).
See the numbers
Net profit of Dr. Reddy's and Zydus Lifesciences by financial year, ₹ crore
Dr. Reddy's yearDr. Reddy's net profitZydus Lifesciences yearZydus Lifesciences net profit
FY22₹2,183 crFY22₹4,487 cr
FY23₹4,507 crFY23₹1,960 cr
FY24₹5,578 crFY24₹3,860 cr
FY25₹5,655 crFY25₹4,526 cr
FY26₹4,196 crFY26₹5,095 cr

Free cash flow

Dr. Reddy's

Zydus Lifesciences

Both charts use the same scale. Indian financial years (April to March); free cash flow = cash from operations minus capital spending, as on each company's page.
See the numbers
Free cash flow of Dr. Reddy's and Zydus Lifesciences by financial year, ₹ crore
Dr. Reddy's yearDr. Reddy's free cash flowZydus Lifesciences yearZydus Lifesciences free cash flow
FY22₹906 crFY22₹902 cr
FY23₹4,001 crFY23₹1,658 cr
FY24₹1,800 crFY24₹2,290 cr
FY25₹1,203 crFY25₹5,087 cr
FY26₹1,833 crFY26−₹555 cr

Sources: Dr. Reddy's S25, S24, S23, S22, S20, S19, S1, S11, S12 · Zydus Lifesciences S4, S5, S3, S2, S1, S6

Growth and net margin, FY22 to FY26

Worked out over the years both pages cover, so the two growth figures use the same span. Net margin is net profit as a share of revenue, as on each page.

Dr. Reddy's

Revenue, per year
+11.8%
Net profit, per year
+17.7%

Zydus Lifesciences

Revenue, per year
+15.8%
Net profit, per year
+3.2%

Cityfort calculation: compound growth per year from FY22 to FY26 (4 years), from each page's yearly numbers, as reported.

Net margin by year
Net margin (net profit as a share of revenue) of Dr. Reddy's and Zydus Lifesciences by financial year, as on each page
YearDr. Reddy'sZydus Lifesciences
FY2210.1%29.7%
FY2318.3%11.4%
FY2419.9%19.7%
FY2517.3%19.5%
FY2612.5%18.8%

Sources: Dr. Reddy's S25, S24, S23, S22, S20, S19, S1, S11, S12 · Zydus Lifesciences S4, S5, S3, S2, S1, S6

Latest quarter, against the same quarter a year earlier

Each page's latest quarter as reported; the change is a Cityfort calculation.

Dr. Reddy's

Q2 FY27, the quarter to 30 Sep 2026, against Q2 FY26

Dr. Reddy's, Q2 FY27 against Q2 FY26
MeasureQ2 FY27Q2 FY26Change
Revenue₹8,698 cr₹8,828 cr−1.5%
Net profit₹925 cr₹1,347 cr−31.3%

Zydus Lifesciences

Q2 FY27, the quarter to 30 Sep 2026, against Q2 FY26

Zydus Lifesciences, Q2 FY27 against Q2 FY26
MeasureQ2 FY27Q2 FY26Change
Revenue₹7,910 cr₹6,123 cr+29.2%
Net profit₹926 cr₹1,261 cr−26.6%

Sources: Dr. Reddy's S17, S14, S11, S12, S7, S8, S3, S4 · Zydus Lifesciences S6, S9, S8

Who pays each company

Dr. Reddy's

  • Buyers of finished medicines · 88.9% of revenueWholesalers, distributors, pharmacy chains, hospitals and government institutions buying the Global Generics segment's medicines. Share is of FY26 revenue.
  • Other drug makers · 10.5% of revenueBuy active ingredients and contract research and manufacturing services (PSAI segment). Share is after removing PSAI's sales to Dr. Reddy's own generics business.
  • Others · 0.6% of revenueAurigene Oncology (a drug discovery business) and proprietary products.

Zydus Lifesciences

  • Buyers in the US · 43.2% of revenueGeneric and specialty medicines. One US-based wholesaler owed more than 10% of Zydus's trade receivables on 31 Mar 2026. Share is of FY26 revenue by customer location.
  • Buyers in India · 35.8% of revenueBranded medicines reach patients through a distributor network and chemists, and hospitals buy directly. India also buys Zydus Wellness consumer products.
  • Buyers in Europe · 9.9% of revenueRose from ₹402 crore in FY25 to ₹2,675 crore in FY26, the first year with Amplitude (France) and Comfort Click (UK) in the accounts.
  • Buyers in other countries · 11.2% of revenueMedicines sold in other markets through subsidiaries and distributors.

Sources: Dr. Reddy's S1, S2 · Zydus Lifesciences S1, S6

Revenue by segment

Dr. Reddy's

FY26

Dr. Reddy's revenue by segment, FY26
SegmentRevenueShare
Global Generics₹29,946 cr88.9%
Pharmaceutical Services and Active Ingredients (PSAI)₹3,540 cr10.5%
Others₹214 cr0.6%

Zydus Lifesciences

FY26

Zydus Lifesciences revenue by segment, FY26
SegmentRevenueShare
Pharmaceuticals₹22,412 cr82.6%
Consumer products₹3,954 cr14.6%
Medical technologies₹782 cr2.9%

Sources: Dr. Reddy's S1 · Zydus Lifesciences S1, S6

Where the revenue comes from

Revenue by region, as each company splits it, with the period.

Dr. Reddy's

FY26

  • United States35.1%
  • India19.2%
  • Russia10.4%
  • Other countries35.3%

Zydus Lifesciences

FY26

  • United States43.2%
  • India35.8%
  • Other countries11.2%
  • Europe9.9%

Sources: Dr. Reddy's S1 · Zydus Lifesciences S1

Borrowings and cash

Dr. Reddy's

Borrowings
₹5,826 cr
Cash and investments
₹6,874 cr

On 30 Sep 2026.

On 30 Sep 2026 Dr. Reddy's cash and short-term investments were ₹1,048 crore more than its borrowings (Cityfort calculation from the Q2 FY27 results).

Zydus Lifesciences

Borrowings
₹13,250 cr
Cash and investments
₹5,216 cr

On 30 Sep 2026.

On 30 Sep 2026 Zydus's borrowings were ₹8,034 crore more than its cash and liquid investments; on 31 Mar 2025 its cash had been ₹4,643 crore more than its debt.

Sources: Dr. Reddy's S3, S5, S6, S19, S22, S38 · Zydus Lifesciences S6, S1, S12, S21

Who owns each company

Dr. Reddy's

  • Promoters: 26.6%
  • Foreign institutional investors (FIIs): 20.3%
  • Indian institutions (DIIs): 31.9%
  • Public: 9.9%
  • Shares behind US-listed ADRs (held by JP Morgan Chase Bank as depository; filed inside foreign institutions): 11.1%
  • Pledged: 0.0% of the promoter holding.
  • Shareholding pattern at the end of Q2 FY27.

Zydus Lifesciences

  • Promoters: 75.0%
  • Foreign institutional investors (FIIs): 7.1%
  • Indian institutions (DIIs): 11.3%
  • Public: 6.7%
  • Pledged: 0.0% of the promoter holding.
  • Shareholding pattern at the end of Q2 FY27.

Sources: Dr. Reddy's S26, S27, S28, S29, S30, S31, S32, S33, S34, S35, S36, S37, S42 · Zydus Lifesciences S37, S36, S35, S34, S33, S32, S31, S30, S29, S28, S27, S26, S25

What protects each business

What each page lists as protecting the business from competitors, each with its written reason. These describe business traits, not the share.

Dr. Reddy's

  • Own ingredient supply

    The PSAI segment makes active ingredients and sold ₹727 crore of them to Dr. Reddy's own generics business in FY26. ICRA (Jan 2026) says this backward integration gives a significant cost advantage.

  • Spread across markets

    In FY26 customers in the US paid 35.1% of revenue, India 19.2%, Russia 10.4% and other countries 35.3%. It sold in 87 countries.

  • US filings pipeline

    77 generic and 3 new-drug applications were pending with the US FDA in Sep 2026, including 27 first-to-file.

  • India brands

    The company says, citing IQVIA, it ranked 8th in India in the quarter to Sep 2026, and its India sales grew 21.0% against the market's 14.7%.

  • Cash and borrowings

    On 30 Sep 2026 cash and short-term investments exceeded borrowings by ₹1,048 crore (Cityfort calculation). ICRA rated it AA+/Stable on 9 Jan 2026.

Zydus Lifesciences

  • US generics reach

    Zydus says it was the third-largest generics company in the US by prescriptions (IQVIA, 12 months to Mar 2026). North America formulation sales were ₹11,682 crore in FY26.

  • India brands

    India formulation sales were ₹6,574 crore in FY26, against ₹19,290 crore for Sun Pharma and ₹12,680 crore for Cipla's One India business. Long-term-condition medicines were 56.9% of Zydus's India portfolio (AWACS, Sep 2026).

  • Research and own drugs

    R&D was ₹2,273 crore, 8.4% of FY26 revenue, across 10 R&D centres. Its own new drugs include saroglitazar and desidustat.

  • Plants and approvals

    44 manufacturing facilities. On 31 Mar 2026 none of its plants was under a warning letter, but the Baddi plant received one on 3 Jun 2026.

Sources: Dr. Reddy's S1, S38, S2, S5, S3, S72 · Zydus Lifesciences S1, S14, S57, S58, S12, S51, S59

Where growth could come from

Each page's growth drivers. The status compares progress with what the company itself said it would do; it is not a view on the share.

Dr. Reddy's

  • Semaglutide (diabetes and weight-loss injection) · Behind: behind the company's own plan₹239.7 crore provision, Q1 FY27
  • India · Working: on track against what the company said+17% YoY, Q2 FY27 (company figure)
  • Emerging markets · Working: on track against what the company said+24% YoY, Q2 FY27 (company figure)
  • North America without lenalidomide · Mixed: partly on track₹2,489 crore, −23% YoY, Q2 FY27
  • Europe and nicotine gums · Mixed: partly on track+1% YoY, Q2 FY27 (company figure)
  • Abatacept biosimilar · Early: too early to judgeUS approval awaited

Zydus Lifesciences

  • Branded medicines in India · Working: on track against what the company saidIndia formulations +18.3%, Q2 FY27
  • International markets · Working: on track against what the company said+33.2%, Q2 FY27
  • Consumer wellness · Working: on track against what the company said+76.1%, Q2 FY27
  • US specialty medicines · New: recently announced16% of US sales, Q2 FY27
  • Saroglitazar in the US · New: recently announcedFDA target date 27 Nov 2026
  • Medical devices · Early: too early to judgeSegment loss ₹150 cr, H1 FY27

Sources: Dr. Reddy's S64, S67, S41, S8, S70, S5, S12, S38, S6, S48 · Zydus Lifesciences S12, S14, S6, S52, S50, S21

Dividends, buybacks, auditor and credit rating

Dividends per share and buybacks for up to five years, the statutory auditor and the latest credit rating, as each page records them.

Dr. Reddy's

  • Dividends per shareFY22: ₹6.00 (22.8% of profit) · FY23: ₹8.00 (14.7% of profit) · FY24: ₹8.00 (11.9% of profit) · FY25: ₹8.00 (11.8% of profit) · FY26: ₹8.00 (15.9% of profit)
  • BuybacksNone on the page in the last five years.
  • AuditorDeloitte Haskins & Sells LLP, since 2026
  • Credit ratingICRA: [ICRA]AA+ (long-term bank limits, ₹2,000 crore), outlook Stable (9 Jan 2026)

Zydus Lifesciences

  • Dividends per shareFY22: ₹2.50 (5.7% of profit) · FY23: ₹6.00 (31.1% of profit) · FY24: ₹3.00 (7.9% of profit) · FY25: ₹11.00 (24.5% of profit) · FY26: ₹1.00 (2.0% of profit)
  • Buybacks
    • 19 Jul 2022: Bought back 11,538,461 shares at ₹650 each (₹750 crore); the FY24 annual report says the shares were extinguished on 19 Jul 2022. The FY23 cash flow shows ₹863 crore paid including tax and costs. (₹750 cr)
    • 15 Mar 2024: Bought back 5,970,149 shares at ₹1,005 each (₹600 crore); the FY24 annual report says the shares were extinguished on 15 Mar 2024. The promoter's Zydus Family Trust received ₹387 crore. (₹600 cr)
    • 18 Jun 2026: Tender-offer buyback approved by the board on 19 May 2026: 8,730,158 shares (0.87%) bought at ₹1,260, raised from ₹1,150 on 27 May 2026, and extinguished on 18 Jun 2026. ₹1,106 crore paid including expenses; the promoter holding was 75.01% afterwards. (₹1,100 cr)
  • AuditorDeloitte Haskins & Sells LLP
  • Credit ratingCRISIL: AAA (long term), A1+ (short term), outlook Stable (10 Sep 2026)

Sources: Dr. Reddy's S1, S25, S24, S22, S19, S12, S11, S46, S38 · Zydus Lifesciences S1, S5, S3, S2, S6, S35, S38

Risks only one page tracks

Risks whose type the other company's page does not list. Both pages track risks of these types: regulation, execution, legal cases, liquidity. Every risk is on each company's page.

Dr. Reddy's

  • Price competition in US generics (competition)US customers paid 35.1% of FY26 revenue, down from 45.9% in FY25. After lenalidomide exclusivity ended in Jan 2026, North America revenue fell 23% in Q2 FY27 (company figure). ICRA lists US generics price competition as a challenge.

Zydus Lifesciences

  • US generic prices and competition (pricing)US buyers paid 43.2% of FY26 revenue. CRISIL's Dec 2024 report notes price erosion in US generics. When giving the FY27 margin outlook on 19 May 2026, Dr Sharvil Patel cited competition for lenalidomide and mirabegron and saroglitazar launch costs.
  • Debt after acquisitions (debt)Net debt (Cityfort calculation) went from net cash of ₹4,643 crore on 31 Mar 2025 to ₹8,034 crore on 30 Sep 2026. The company put net debt at 0.62 times EBITDA on its own measure on 30 Sep 2026. CRISIL reaffirmed AAA/Stable on 10 Sep 2026.
  • One large customer (customer or supplier concentration)One customer, not named, paid ₹3,364 crore, 12.4% of FY26 revenue. One US-based wholesaler owed more than 10% of trade receivables on 31 Mar 2026.

Sources: Dr. Reddy's S1, S5, S38 · Zydus Lifesciences S1, S39, S23, S12, S6, S38, S21

Key facts

How does Dr. Reddy's make money compared with Zydus Lifesciences?
Dr. Reddy's revenue by segment in FY26: Global Generics 88.9%, Pharmaceutical Services and Active Ingredients (PSAI) 10.5%, Others 0.6%. Zydus Lifesciences' revenue by segment in FY26: Pharmaceuticals 82.6%, Consumer products 14.6%, Medical technologies 2.9%.
Which is bigger by revenue, Dr. Reddy's or Zydus Lifesciences?
Dr. Reddy's reported revenue of ₹33,700 cr in FY26, and Zydus Lifesciences reported revenue of ₹27,148 cr in FY26.
How much net profit did Dr. Reddy's and Zydus Lifesciences report?
Dr. Reddy's reported a net profit of ₹4,196 cr in FY26, and Zydus Lifesciences reported ₹5,095 cr in FY26.
How much of every ₹100 did Dr. Reddy's and Zydus Lifesciences keep as profit?
Dr. Reddy's kept ₹12.0 of every ₹100 that came in during FY26, and Zydus Lifesciences kept ₹18.4 in FY26 (Cityfort calculation from each company's annual report).
How much do Dr. Reddy's and Zydus Lifesciences owe, and how much cash do they hold?
Dr. Reddy's had borrowings of ₹5,826 cr and cash and investments of ₹6,874 cr on 30 Sep 2026. Zydus Lifesciences had borrowings of ₹13,250 cr and cash and investments of ₹5,216 cr on 30 Sep 2026.
Who owns Dr. Reddy's and Zydus Lifesciences?
Promoters held 26.6% of Dr. Reddy's shares at the end of Q2 FY27, with none of it pledged. Promoters held 75.0% of Zydus Lifesciences' shares at the end of Q2 FY27, with none of it pledged. Both come from the shareholding patterns the companies filed with NSE and BSE.
When do Dr. Reddy's and Zydus Lifesciences' financial years end?
Dr. Reddy's and Zydus Lifesciences both use the Indian financial year, April to March. The latest full year is FY26 on the Dr. Reddy's page and FY26 on the Zydus Lifesciences page.

Sources: Dr. Reddy's S25, S24, S23, S22, S20, S19, S1, S11, S12, S2, S3, S5, S6, S38 · Zydus Lifesciences S4, S5, S3, S2, S1, S6, S12, S21

Built from each company's page. Dr. Reddy's updated 17 Nov 2026; Zydus Lifesciences updated 17 Nov 2026.

Sources

Dr. Reddy's

  1. S1Integrated Annual Report FY2025-26, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 30 Jun 2026
  2. S2Business Responsibility and Sustainability Report FY2025-26, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 30 Jun 2026
  3. S3Q2 FY27 consolidated financial results (Ind AS, NSE XBRL), NSE (company filing), 23 Oct 2026
  4. S4Q2 FY27 results filing: board outcome and financial results (PDF), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 23 Oct 2026
  5. S5Q2 FY27 results presentation (IFRS), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 23 Oct 2026
  6. S6Q2 FY27 earnings call transcript (23 Oct 2026), Dr. Reddy's Laboratories Ltd (company website; filed with NSE/BSE 29 Oct 2026), 29 Oct 2026
  7. S7Q1 FY27 consolidated financial results (Ind AS, NSE XBRL), NSE (company filing), 22 Jul 2026
  8. S8Q1 FY27 results filing (PDF, notes), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 22 Jul 2026
  9. S11Q4 FY26 and FY26 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 12 May 2026
  10. S12Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 12 May 2026
  11. S14Q3 FY26 consolidated financial results (Ind AS, NSE XBRL), NSE (company filing), 21 Jan 2026
  12. S17Q2 FY26 consolidated financial results (Ind AS, NSE XBRL), NSE (company filing), 24 Oct 2025
  13. S19Q4 FY25 and FY25 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 9 May 2025
  14. S20Q4 FY25 results filing (PDF; FY24 comparatives and split-adjusted EPS), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 9 May 2025
  15. S22Q4 FY24 and FY24 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 7 May 2024
  16. S23Q4 FY24 results filing (PDF; FY23 comparatives), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 7 May 2024
  17. S24Q4 FY23 and FY23 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 10 May 2023
  18. S25Q4 FY22 and FY22 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 19 May 2022
  19. S26Shareholding pattern as of Dec 2023 (NSE XBRL), NSE (company filing), 19 Jan 2024
  20. S27Shareholding pattern as of Mar 2024 (NSE XBRL), NSE (company filing), 19 Apr 2024
  21. S28Shareholding pattern as of Jun 2024 (revised filing) (NSE XBRL), NSE (company filing), 19 Jul 2024
  22. S29Shareholding pattern as of Sep 2024 (NSE XBRL), NSE (company filing), 21 Oct 2024
  23. S30Shareholding pattern as of Dec 2024 (NSE XBRL), NSE (company filing), 21 Jan 2025
  24. S31Shareholding pattern as of Mar 2025 (NSE XBRL), NSE (company filing), 19 Apr 2025
  25. S32Shareholding pattern as of Jun 2025 (NSE XBRL), NSE (company filing), 21 Jul 2025
  26. S33Shareholding pattern as of Sep 2025 (NSE XBRL), NSE (company filing), 16 Oct 2025
  27. S34Shareholding pattern as of Dec 2025 (NSE XBRL), NSE (company filing), 20 Jan 2026
  28. S35Shareholding pattern as of Mar 2026 (revised filing) (NSE XBRL), NSE (company filing), 21 Jul 2026
  29. S36Shareholding pattern as of Jun 2026 (NSE XBRL), NSE (company filing), 21 Jul 2026
  30. S37Shareholding pattern as of Sep 2026 (NSE XBRL), NSE (company filing), 21 Oct 2026
  31. S38ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable), ICRA Ltd, 9 Jan 2026
  32. S41Intimation: semaglutide batches out of specification due to API issue; supplies delayed, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 9 Jul 2026
  33. S42Disclosure: promoters transfer 20.58% to VSD Family Trust and GVP Family Trust, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 18 Sep 2025
  34. S46AGM 23 Jul 2026 outcome: Deloitte Haskins & Sells LLP appointed statutory auditors; director appointments, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 23 Jul 2026
  35. S48Intimation: US FDA pre-license inspection at biologics facility, Bachupally: Form 483 with 7 observations, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 25 Jun 2026
  36. S64Press release: launch of semaglutide injection (Obeda) in India, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 21 Mar 2026
  37. S67Press release: launch of generic semaglutide injection in Canada, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 16 May 2026
  38. S70Press release: marketing authorization for generic semaglutide injection in Brazil, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 5 Nov 2026
  39. S72Sun Pharmaceutical Industries: investor presentation, September 2026 ("Creating Lasting Value"), India market share chart (AIOCD AWACS, MAT Jun 2026), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 22 Sep 2026

Zydus Lifesciences

  1. S1Integrated Annual Report 2025-26 (FY26), Zydus Lifesciences Ltd (company IR site), 30 Jun 2026
  2. S2Annual Report 2024-25 (FY25), Zydus Lifesciences Ltd (company IR site), 3 Jul 2025
  3. S3Annual Report 2023-24 (FY24), Zydus Lifesciences Ltd (company IR site), 12 Jul 2024
  4. S4Annual Report 2022-23 (FY23), Zydus Lifesciences Ltd (company IR site), 18 May 2023
  5. S5Annual Report 2021-22 (FY22), Zydus Lifesciences Ltd (company IR site), 15 Jul 2022
  6. S6Q2 FY27 results (standalone and consolidated, with notes and balance sheet), Zydus Lifesciences Ltd (company IR site), 4 Nov 2026
  7. S8Q4 FY26 and FY26 audited results, Zydus Lifesciences Ltd (company IR site), 19 May 2026
  8. S9Q3 FY26 results, Zydus Lifesciences Ltd (company IR site), 9 Feb 2026
  9. S12Press release: financial performance for Q2 and H1 FY27, Zydus Lifesciences Ltd (company IR site), 4 Nov 2026
  10. S14Press release: financial performance for Q4 and full year FY26, Zydus Lifesciences Ltd (company IR site), 19 May 2026
  11. S21Q2 FY27 earnings call transcript (call 4 Nov 2026), Zydus Lifesciences Ltd (company IR site), 7 Nov 2026
  12. S23Q4 FY26 earnings call transcript (call 19 May 2026), Zydus Lifesciences Ltd (company IR site), 24 May 2026
  13. S25Shareholding pattern as of 31 Dec 2023, Zydus Lifesciences Ltd (company IR site), 8 Jan 2024
  14. S26Shareholding pattern as of 31 Mar 2024, Zydus Lifesciences Ltd (company IR site), 9 Apr 2024
  15. S27Shareholding pattern as of 30 Jun 2024, Zydus Lifesciences Ltd (company IR site), 11 Jul 2024
  16. S28Shareholding pattern as of 30 Sep 2024, Zydus Lifesciences Ltd (company IR site), 9 Oct 2024
  17. S29Shareholding pattern as of 31 Dec 2024, Zydus Lifesciences Ltd (company IR site), 20 Jan 2025
  18. S30Shareholding pattern as of 31 Mar 2025, Zydus Lifesciences Ltd (company IR site), 12 Apr 2025
  19. S31Shareholding pattern as of 30 Jun 2025, Zydus Lifesciences Ltd (company IR site), 18 Jul 2025
  20. S32Shareholding pattern as of 30 Sep 2025, Zydus Lifesciences Ltd (company IR site), 14 Oct 2025
  21. S33Shareholding pattern as of 31 Dec 2025 (revised), Zydus Lifesciences Ltd (company IR site), 27 May 2026
  22. S34Shareholding pattern as of 31 Mar 2026, Zydus Lifesciences Ltd (company IR site), 9 Apr 2026
  23. S35Shareholding pattern as of 18 Jun 2026 (post-buyback, Reg 31(1)(c)), Zydus Lifesciences Ltd (company IR site), 24 Jun 2026
  24. S36Shareholding pattern as of 30 Jun 2026, Zydus Lifesciences Ltd (company IR site), 11 Jul 2026
  25. S37Shareholding pattern as of 30 Sep 2026, Zydus Lifesciences Ltd (company IR site), 7 Oct 2026
  26. S38Intimation of credit rating: CRISIL letters dated 10 Sep 2026 (AAA/Stable, A1+ reaffirmed); rationale attached as scanned images, Zydus Lifesciences Ltd (filed with NSE), 11 Sep 2026
  27. S39CRISIL Ratings rating rationale, Zydus Lifesciences Ltd, 27 Dec 2024, CRISIL Ratings Ltd, 27 Dec 2024
  28. S50Update: US FDA Priority Review for saroglitazar NDA in PBC, PDUFA date 27 Nov 2026, Zydus Lifesciences Ltd (exchange disclosure, company IR site), 27 May 2026
  29. S51Receipt of USFDA warning letter for the Baddi formulations facility, Zydus Lifesciences Ltd (exchange disclosure, company IR site), 3 Jun 2026
  30. S52Completion of acquisition and merger of Assertio Holdings Inc., Zydus Lifesciences Ltd (exchange disclosure, company IR site), 16 Jun 2026
  31. S57Press release: Sun Pharma reports Q4FY26 and FY26 results (peer filing), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 22 May 2026
  32. S58Press release: Q4 FY26 and FY26 results (peer filing), Cipla Ltd (filed with NSE), 13 May 2026
  33. S59Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (peer filing), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 12 May 2026

Disclaimer

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.

Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.

Read the full disclaimer

Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.

All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.

Statements by company management are reported as statements, with their date and source; they are not our forecasts.